Home    Back

Zanubrutinib 80 mg    (DrugBank: Zanubrutinib)

1 disease
IDDisease name (Link within this page)Number of trials
300IgG4-related disease1

300. IgG4-related disease    [ 31 clinical trials,   33 drugs,   (DrugBank: 16 drugs),   11 drug target genes,   81 drug target pathways]
Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 31 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04602598
(ClinicalTrials.gov)		January 202120/10/2020Zanubrutinib in Patients With IgG4-Related DiseaseA Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients With IgG4-Related DiseaseIgG4 Related DiseaseDrug: Zanubrutinib 80 MGMatthew C. BakerStanford UniversityNot yet recruiting18 Years85 YearsAll10Phase 2United States